group of doctors wearing lab coat and protective mask

Peripheral Interventions

Our focus

We are dedicated to transforming the lives of patients through minimally invasive therapies for cancer and vascular conditions including peripheral artery disease, pulmonary embolism and deep vein thrombosis.

Tony's journey

Delivering meaningful innovation​

Advancing the treatment of vascular conditions ​

We've built a strong portfolio to enable healthcare professionals to treat vascular conditions anywhere in the body excluding the heart. This includes conditions such as peripheral artery disease, pulmonary embolism and deep vein thrombosis. We provide a range of options to visualise inside vessels to diagnose and then treat patients. This includes the use of peripheral imaging technologies and treatments (known as endovascular solutions) that work inside veins and arteries to remove clots and calcium deposits, and prevent further damage.

Next-generation interventional oncology & embolisation technologies

With targeted treatments, we can improve the lives of patients suffering from cancer.
Our interventional oncology and embolisation portfolio is designed to prevent growth and cause destruction of tumours, and includes Selective Internal Radiation Therapy (SIRT) with ytrrium-90 microspheres, coils, beads, ablation technology including cryoablation and radio frequency ablation (RFA), and access and delivery devices.

check icon

150+ products.¹

check icon

Every 16 seconds a Boston Scientific patient is treated with a Peripheral Intervention product.1

check icon

17 active clinical trials in 2023.1

Conditions We Treat  

 
  • Peripheral Artery Disease (PAD)
  • Chronic Limb Threatening Ischemia (CLTI)
  • Deep Vein Thrombosis (DVT) and Post Thrombotic Syndrome (PTS)
  • Pulmonary Embolism (PE)
  • Cancers: Liver (Hepatic Cellular Carcinoma), Colon (metastatic colorectal cancer), Kidney (Renal Cell Carcinoma), Lung, Breast and Prostate, Bone (musculoskeletal and soft tissues)

200M+ 

people suffer from PAD globally.2

765K+

cases of DVT annually in the U.S. and Europe.3

800K

people diagnosed with liver cancer each year globally.4

22M

people suffer from CLTI globally.5

1M

Per 1000 in Europe. Incident rate of PE.⁶

Products and solutions we offer

 
 
Endovascular solutions​
  • Drug-Eluting Technologies​
  • Vessel Preparation and Crossing Technology​
  • Peripheral Balloons and Stents​
  • Guidewires & Accessories

 

Interventional Oncology & Embolisation​
  • Cancer Therapies​
  • Tumour Ablation and Treatments
  • Cryoablation
  • Embolisation​​

   Product spotlight​

Eluvia™ Drug-Eluting Vascular Stent System

Eluvia™ Drug-Eluting Vascular Stent System​

The Eluvia™ Drug-Eluting Vascular Stent System is specifically developed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The Eluvia stent utilises a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery. The Eluvia stent was approved by the FDA based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first head-to-head drug-eluting stent trial in the superficial femoral artery.

Learn more about the Eluvia stent
Ranger™ Drug-Coated Balloon 

RangerTM Drug Coated Balloon

The Ranger™ Drug-Coated Balloon (DCB) was developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The Ranger DCB was designed with a low therapeutic drug dose and proprietary coating which efficiently transfers the drug into the diseased tissue, resulting in high primary patency rates and low systemic drug exposure for patients.

Learn more about the Ranger DCB
TheraSphere™

TheraSphere™ Y-90 Glass Microspheres​

TheraSphereTM is a radioembolisation treatment for patients diagnosed with all hepatic malignancies. A targeted therapy, TheraSphere consists of millions of glass microspheres containing radioactive yttrium-90 that are delivered into the hepatic artery to selectively target and destroy tumour cells while minimising distribution and impact to normal tissue. The radioactive microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment.​

Learn more about Therasphere
TheraSphere™

ICEfx™ Cryoablation System

The ICEfx™ Cryoablation System is the next generation of ablation systems with a compact design and interface that offers predictable, reliable performance and seamless therapy delivery with the exceptional ease of technical operation. ICEfx is designed for interventional oncologists who want to offer their patients on-demand access to state of the art ablation technology. ICEfx effectively treats a wide range of indications: renal masses, lung metastases, prostate cancer, hepatic metastases, and bone metastases.

Learn more about ICEfx
EKOS Acoustic Pulse Thrombolysis™ System

AVVIGO™+ Multi-Modality Guidance System

The AVVIGOTM+ Guidance System is an intuitive, easy-to-use system to perform intravascular imaging and physiology procedures.
Intravascular Ultrasound (IVUS) peripheral imaging using the OptiCrossTM 18 and OpticrossTM 35 catheters with the AVVIGO+ system offers high-quality imaging which enables physicians to properly diagnose disease and personalise treatment. 

Learn more about AVVIGO+ Guidance System​

See what's new

Animation of Boston Scientific WATCHMAN FLX being placed within heart valve.

Patients and innovation

Walking pain-free after treatment for peripheral artery disease

For Tony McDonough, a resident of the U.K. and a person with Type 1 diabetes, peripheral artery disease (PAD) was more than just a medical condition - it was a life-altering challenge.

Read Tony's story
Animation of Boston Scientific WATCHMAN FLX being placed within heart valve.

Patients and innovation

Eight years on from his liver cancer diagnosis, Martyn Griffiths is cancer free

Following treatment with TheraSphere Y90 Glass Microspheres then surgery, Griffiths is back to enjoying life again.

Read Martyn's story
Animation of Boston Scientific WATCHMAN FLX being placed within heart valve.

Patients and innovation

The power of personalised medicine to target liver cancer

Improvements in a therapy that targets liver tumours while limiting radiation exposure to healthy surrounding tissue are significantly increasing the survival time of patients with liver cancer,...

Learn more

                                                                                                                                                

Sources

1. Data on file at Boston Scientific

2. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001153

3. https://academic.oup.com/eurheartj/article/43/36/3379/6586212

4. https://www.cancer.org/cancer/types/liver-cancer/about/what-is-key-statistics.html

5. https://www.jvascsurg.org/article/S0741-5214(23)00284-7/fulltext

6. Torbicki A, Perrier A, Konstantidines S, et al. Guidelines 

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.